• Publications
  • Influence
Dabigatran versus warfarin in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Cardiac-resynchronization therapy for mild-to-moderate heart failure.
TLDR
Among patients with NYHA class II or III heart failure, a wide QRS complex, and left ventricular systolic dysfunction, the addition of CRT to an ICD reduced rates of death and hospitalization for heart failure.
Effect of dronedarone on cardiovascular events in atrial fibrillation.
TLDR
Dronedarone reduced the incidence of hospitalization due to cardiovascular events or death in patients with atrial fibrillation and had higher rates of bradycardia, QT-interval prolongation, nausea, diarrhea, rash and an increased serum creatinine level than the placebo group.
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
TLDR
A 20% relative risk reduction occurred in all-cause mortality and a 33% reduction occur in arrhythmic mortality with ICD therapy compared with amiodarone; this reduction did not reach statistical significance.
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.
TLDR
Prophylactic ICD therapy does not reduce overall mortality in high-risk patients who have recently had a myocardial infarction, and is associated with a reduction in the rate of death due to arrhythmia, that was offset by an increase in the rates of death from nonarrhythmic causes.
Apixaban in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.
Newly identified events in the RE-LY trial.
TLDR
After discussions with the Food and Drug Administration, the primary and secondary efficacy and safety data were checked for consistency, and the study database was reevaluated for possible underreporting of events.
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy
TLDR
In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged <75 years and in those aged ≥75 years.
Subclinical atrial fibrillation and the risk of stroke.
TLDR
Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, occurred frequently in patients with pacemakers and were associated with a significantly increased risk of ischemic stroke or systemic embolism.
...
1
2
3
4
5
...